Blood protein coating of gold nanoparticles as potential tool for organ targeting

Biomaterials

Volumn 35, Issue 10, 2014, Pages 3455-3466

  Schäffler, Martin ^a   Sousa, Fernanda ^b   Wenk, Alexander ^a   Sitia, Leopoldo ^c   Hirn, Stephanie ^a,d   Schleh, Carsten ^a,e   Haberl, Nadine ^a,d   Violatto, Martina ^c   Canovi, Mara ^c   Andreozzi, Patrizia ^b   Salmona, Mario ^c   Bigini, Paolo ^c   Kreyling, Wolfgang G ^a   Krol, Silke ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Abteilung Gesundheitsschutz   (Germany)

Author keywords

Albumin; Apolipoprotein E; Biodistribution; Biokinetics; Blood brain barrier; Protein gold nanoparticle conjugate

Indexed keywords

ALBUMIN; APOLIPOPROTEIN E; BIODISTRIBUTIONS; BIOKINETICS; BLOOD-BRAIN BARRIER; GOLD NANOPARTICLES;

DRUG DELIVERY; GOLD; LIPOPROTEINS; MEDICAL NANOTECHNOLOGY; METAL NANOPARTICLES;

GOLD COATINGS;

APOLIPOPROTEIN E; GOLD 198; GOLD NANOPARTICLE; HUMAN SERUM ALBUMIN;

ARTICLE; BRAIN; CONJUGATION; CONTROLLED STUDY; ENDOTHELIUM; HIPPOCAMPUS; LIVER; LUNG; MOUSE; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; SPLEEN; TARGET ORGAN;

MURINAE;

ALBUMIN; APOLIPOPROTEIN E; BIODISTRIBUTION; BIOKINETICS; BLOOD-BRAIN BARRIER; PROTEIN GOLD NANOPARTICLE CONJUGATE;

BLOOD PROTEINS; DRUG DELIVERY SYSTEMS; FLUORESCENT DYES; GOLD; METAL NANOPARTICLES; TISSUE DISTRIBUTION;

EID: 84893698840     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.100     Document Type: Article

References (53)

1. Ulbrich K., Knobloch T., Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target 2011, 19:125-132.
2. Pardridge W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003, 3:90-105. 51.
3. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002, 10:317-325.
4. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K a Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A 2008, 105:14265-14270.
5. Dell'Orco D., Lundqvist M., Oslakovic C., Cedervall T., Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One 2010, 5:e10949.
6. Casals E., Pfaller T., Duschl A., Oostingh G.J., Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 2010, 4:3623-3632.
7. Arvizo R.R., Giri K., Moyano D., Miranda O.R., Madden B., Daniel J., et al. Identifying new therapeutic targets via modulation of protein Corona formation by engineered nanoparticles. PlosOne 2012, 7.
8. Monopoli M.P., Walczyk D., Campbell A., Elia G., Lynch I., Bombelli F.B., et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011, 133:2525-2534.
9. Tenzer S., Docter D., Rosfa S., Wlodarski A., Kuharev J., Rekik A., et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 2011, 5:7155-7167.
10. Lundqvist M., Stigler J., Cedervall T., Berggård T., Flanagan M.B., Lynch I., et al. The evolution of the protein corona around nanoparticles: a test study. ACS Nano 2011, 5:7503-7509.
11. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60:1615-1626.
12. Liu W., Rose J., Plantevin S., Auffan M., Bottero J.-Y., Vidaud C. Protein corona formation for nanomaterials and proteins of a similar size: hard or soft coronaα. Nanoscale 2013, 5:1658-1668.
13. Dobrovolskaia M.A., Patri A.K., Zheng J., Clogston J.D., Ayub N., Aggarwal P., et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine 2009, 5:106-117.
14. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009, 61:428-437.
15. Lipka J., Semmler-Behnke M., Sperling R a, Wenk A., Takenaka S., Schleh C., et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 2010, 31:6574-6581.
16. Schäffler M., Semmler-Behnke M., Sarioglu H., Takenaka S., Wenk A., Schleh C., et al. Serum protein identification and quantification of the corona of 5, 15 and 80 nm gold nanoparticles. Nanotechnology 2013, 24:265103.
17. Nicholson J.P., Wolmarans M.R., Park G.R. The role of albumin in critical illness. Br J Anaesth 2000, 85:599-610.
18. Ghinea N., Fixman a, Alexandru D., Popov D., Hasu M., Ghitescu L., et al. Identification of albumin-binding proteins in capillary endothelial cells. J Cell Biol 1988, 107:231-239.
19. Sousa F., Mandal S., Garrovo C., Astolfo A., Bonifacio A., Latawiec D., et al. Functionalized gold nanoparticles: a detailed in vivo multimodal microscopic brain distribution study. Nanoscale 2010, 2:2826-2834.
20. Hirn S., Semmler-Behnke M., Schleh C., Wenk A., Lipka J., Schäffler M., et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 2011, 77:407-416.
21. Semmler-Behnke M., Kreyling W.G., Lipka J., Fertsch S., Wenk A., Takenaka S., et al. Biodistribution of 1.4- and 18-nm gold particles in rats. Small 2008, 4:2108-2111.
22. Schleh C., Semmler-Behnke M., Lipka J., Wenk A., Hirn S., Schäffler M., et al. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology 2012, 6:36-46.
23. Beisiegel U., Weber W., Ihrke G., Herz J., Stanley K.K. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989, 341:162-164.
24. Rudenko G., Henry L., Henderson K., Ichtchenko K., Brown M.S., Goldstein J.L., et al. Structure of the LDL receptor extracellular domain at endosomal pH. Science 2002, 298:2353-2358.
25. Ramasamy I. Recent advances in physiological lipoprotein metabolism. Clin Chem Lab Med 2013, 1-33.
26. Niemeier A., Gàfvels M., Heeren J., Meyer N., Angelin B., Beisiegel U. VLDL receptor mediates the uptake of human chylomicron remnants in vitro. J Lipid Res 1996, 37:1733-1742.
27. Turkevich J., Stevenson P.C., Hillier J. A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc 1951, 11:55-75.
28. Ai Tran H.N., Sousa F., Moda F., Mandal S., Chanana M., Vimercati C., et al. A novel class of potential prion drugs: preliminary in vitro and in vivo data for multilayer coated gold nanoparticles. Nanoscale 2010, 2:2724-2732.
29. Mandal S., Bonifacio A., Zanuttin F., Sergo V., Krol S. Synthesis and multidisciplinary characterization of polyelectrolyte multilayer-coated nanogold with improved stability toward aggregation. Colloid Polym Sci 2010, 289:269-280.
30. Bigini P., Gardoni F., Barbera S., Cagnotto A., Fumagalli E., Longhi A., et al. Expression of AMPA and NMDA receptor subunits in the cervical spinal cord of wobbler mice. BMC Neurosci 2006, 7:71.
31. Kreyling W.G., Hirn S., Schleh C. Nanoparticles in the lung. Nat Biotechnol 2010, 28:1275-1276.
32. Oeff K., Koenig A. Das Blutvolumen einiger Rattenorgane und ihre Restblutmenge nach Entbluten bzw. Durchspuelung. Bestimmung mit P32-markierten Erythrocyten. Arch Exper Path u Pharmakol 1955, 226:98-102.
33. Hushcha T.O., Luik a I., Naboka Y.N. Conformation changes of albumin in its interaction with physiologically active compounds as studied by quasi-elastic light scattering spectroscopy and ultrasonic method. Talanta 2000, 53:29-34.
34. Fogh-Andersen N., Bjerrum P.J., Siggaard-Andersen O. Ionic binding, net charge, and Donnan effect of human serum albumin as a function of pH. Clin Chem 1993, 39:48-52.
35. Ahmad K.M., Oh S.S., Kim S., McClellen F.M., Xiao Y., Soh H.T. Probing the limits of aptamer affinity with a microfluidic SELEX platform. PLoS One 2011, 6:e27051.
36. Hatters D.M., Peters-Libeu C.A., Weisgraber K.H. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006, 31:445-454.
37. Morais T., Soares M.E., Duarte J.A., Soares L., Maia S., Gomes P., et al. Effect of surface coating on the biodistribution profile of gold nanoparticles in the rat. Eur J Pharm Biopharm 2012, 80:185-193.
38. Balogh L., Nigavekar S.S., Nair B.M., Lesniak W., Zhang C., Sung L.Y., et al. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomedicine Nanotechnol Biol Med 2007, 3:281-296.
39. Sonavane G., Tomoda K., Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 2008, 66:274-280.
40. Röcker C., Pötzl M., Zhang F., Parak W.J., Nienhaus G.U. A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. Nat Nanotechnol 2009, 4:577-580.
41. Walczyk D., Bombelli F.B., Monopoli M.P., Lynch I., Dawson K.A. What the cell "sees" in bionanoscience. J Am Chem Soc 2010, 132:5761-5768.
42. Krol S. Challenges in drug delivery to the brain: nature is against us. J Control Release 2012, 164:145-155.
43. Huang Y. Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr Opin Lipidol 2010, 21:337-345.
44. Han J., Wang Q., Zhang Z., Gong T., Sun X. Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer. Small 2013, 10.1002/smll.201301992.
45. Howell M., Wang C., Mahmoud A., Hellermann G., Mohapatra S.S., Mohapatra S. Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: perspectives and challenges for use in lung diseases. Drug Deliv Transl Res 2013, 3:352-363.
46. Jong WH De, Burger M.C., Verheijen M.a., Geertsma R.E. Detection of the presence of gold nanoparticles in organs by transmission electron microscopy. Mater (Basel) 2010, 3:4681-4694.
47. Balasubramanian S.K., Jittiwat J., Manikandan J., Ong C.-N., Yu L.E., Ong W.-Y. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials 2010, 31:2034-2042.
48. De Jong W.H., Hagens W.I., Krystek P., Burger M.C., Sips AJ.a M., Geertsma R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29:1912-1919.
49. Shankar G., Pendley C., Stein K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 2007, 25:555-561.
50. Johansen P., Senti G., Martínez Gómez J.M., Wüthrich B., Bot A., Kündig T.M. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur J Immunol 2005, 35:3591-3598.
51. Teichroeb J.H., Forrest J a, Jones L.W. Size-dependent denaturing kinetics of bovine serum albumin adsorbed onto gold nanospheres. Eur Phys J E Soft Matter 2008, 26:411-415.
52. Peng Q., Zhang S., Yang Q., Zhang T., Wei X.-Q., Jiang L., et al. Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. Biomaterials 2013, 34:8521-8530.
53. Oka K., Ishimura-Oka K., Chu M.J., Sullivan M., Krushkal J., Li W.H., et al. Mouse very-low-density-lipoprotein receptor (VLDLR) cDNA cloning, tissue-specific expression and evolutionary relationship with the low-density-lipoprotein receptor. Eur J Biochem 1994, 224:975-982.